• Challenge
  • Create
  • Transform
  • info@imaginab.com
  • +1310.645.1211
  • Order now
  • Supplier Login
ImaginAb
  • About
  • Pipeline
  • Technology
  • Clinical Trials
  • News
  • Knowledge Hub
  • Contact Us
  • About
    • About
    • Meet Team ImaginAb
    • Careers
    • Partnerships
  • Pipeline
  • Technology
    • Technology
    • CD8 ImmunoPET
    • Radiopharmaceutical Therapy
  • Clinical Trials
  • News
  • Knowledge Hub
  • Contact Us

About

Visit About page
  • Meet Team ImaginAb
  • Careers
  • Partnerships

Pipeline

Visit Pipeline page

Technology

Visit Technology page
  • CD8 ImmunoPET
  • Radiopharmaceutical Therapy

Clinical Trials

Visit Clinical Trials page

News

Visit News page

Knowledge Hub

Visit Knowledge Hub page

Contact Us

Visit Contact Us page
News & Events

Keep up to date with the latest news and events.

  • Home
  • News & Events
  • All
  • News
  • Events
  • Webinars
news
news

ImaginAb Launches Phase II C-IT Neo Trial using CD8+ Cell Imaging to Investigate Neoadjuvant Immunotherapy

14 Dec 2022

news
news

ImaginAb Announces new Clinical Trial at Hull University Teaching Hospitals NHS Trust to Investigate CD8 ImmunoPET in Patients with Renal Cancer and Malignant Melanoma

06 Dec 2022

news
news

ImaginAb Executes New License and Supply Agreement for CD8 ImmunoPET Technology with TriSalus Life Sciences

22 Nov 2022

news
news

ImaginAb Executes License and Supply Agreement for CD8 ImmunoPET Technology with DynamiCure Biotechnology

15 Nov 2022

news
news

Parthenon Therapeutics and ImaginAb Announce License and Supply Agreement to Advance New Class of Anti-Cancer Therapies’ Clinical Development Program

10 Nov 2022

news
news

ImaginAb Announces First Patient Dosed in Australia in Phase IIb iPREDICT Trial

25 Oct 2022

news
news

ImaginAb and Cyclotek Enter into Manufacturing and Distribution Agreement for CD8 ImmunoPET Agent in Australia

17 Oct 2022

news
news

A Transformational Year: ImaginAb expands Pipeline to include Radiopharmaceutical Therapies, enters Multiple Partnerships, and Drives Forward Development of Investigational CD8 ImmunoPET Agent

04 Oct 2022

news
news

UC Davis' new research shows how total-body PET imaging can assess the immunological response to COVID-19 infections

10 Aug 2022

news
news

Women of Color in Biopharma: Overcoming Barriers and Fighting for a Seat at the Table [Anna Wu, ImaginAb Founder featured]

20 Jul 2022

news
news

ImaginAb and DuChemBio Announce Manufacturing and Distribution Partnership

16 Jun 2022

news
news

Society of Nuclear Medicine and Molecular Imaging Announces 2022 Fellows- Anna Wu Recognized as 2022 Fellow

13 Jun 2022

news
news

ImaginAb and PharmaLogic Enter into Manufacturing and Distribution Agreement for CD8 ImmunoPET agent Zirconium 89 Crefmirlimab Berdoxam in USA

10 Jun 2022

news
news

Monrol and ImaginAb Announce Supply, Manufacturing and Distribution Partnership

09 Jun 2022

news
news

ImaginAb and Roche have entered a clinical trial supply agreement for provision of atezolizumab (Tecentriq®)1 to Non-Small Cell Lung Cancer Patients Enrolled in ImaginAb’s iPREDICT Phase IIb Study

08 Jun 2022

news
news

Imaging Endpoints to Supply Clinical Doses of CD8 Imaging Agent to BioPharma Companies

03 Jun 2022

news
news

ImaginAb and [Yantai] DongCheng Pharmaceutical Group Sign Exclusive License Agreement to Commercialize CD8 ImmunoPET Agent in China to Serve Pharma and Healthcare Community

24 May 2022

news
news

ImaginAb announces a new supply agreement with Invicro to offer clinical doses of CD8 investigational ImmunoPET imaging agent for Immuno-Oncology preclinical and clinical studies

12 May 2022

news
news

ImaginAb Announces New Supply Agreement to Supply Genmab A/S with its investigational CD8 ImmunoPET agent

05 May 2022

news
news

CD8 - Targeted PET Imaging Study is Front Cover News of the Journal of Nuclear Medicine in May 2022 Edition

04 May 2022

news
news

ImaginAb Eliminates 1.7k Hours of AP Workload and the Need to Hire Additional Headcount

15 Mar 2022

news
news

SHINE Technologies and ImaginAb Announce Lutetium-177 Clinical Supply Agreement

09 Mar 2022

news
news

ImaginAb Inc. and DongCheng Pharmaceutical Group Announce Plans for a CD8 ImmunoPET Commercial Partnership

25 Jan 2022

news
news

ImaginAb formally launches Phase IIb 'iPREDICT' study to prove CD8 ImmunoPET imaging predictivity

20 Jan 2022

news
news

ImaginAb announces major expansion of pipeline as it extends into Radiopharmaceutical Therapies (RPT) to address unmet needs in oncology

07 Jan 2022

news
news

ImaginAb announces License and Supply Agreement with Bayer for CD8 ImmunoPET Technology

16 Dec 2021

news
news

Clinical Grade 89Zr-Oxine Cell Labeling

02 Nov 2021

news
news

ImaginAb announces partnership with Brand Institute to develop a global brand name for CD8 ImmunoPET Technology

29 Oct 2021

news
news

BriaCell declares ImaginAb’s CD8 ImmunoPET as the ‘Holy Grail’

25 Oct 2021

news
news

ImaginAb and Chugai announce new non-exclusive license and supply agreement for CD8 ImmunoPET

01 Sep 2021

news
news

BriaCell and ImaginAb Announce Collaboration to Evaluate Immunotherapy Imaging Technology in Advanced Breast Cancer

19 Aug 2021

news
news

ImaginAb announces extension of long-standing partnership with Boehringer Ingelheim

21 Jul 2021

news
news

ImaginAb announces successful 1st patient dosed in new Immuno Oncology clinical trial into B-cell non-Hodgkin’s Lymphoma

15 Jul 2021

news
news

Abcuro and ImaginAb Share Initial Results of Study Using Novel Technology for Imaging T Cell Infiltration of Skeletal Muscle in Patients with Inclusion Body Myositis

30 Jun 2021

news
news

Innovative method to improve cancer immunotherapy

15 Jun 2021

news
news

ImaginAb completes $12.8 million financing to accelerate growth plans

03 Jun 2021

news
news

ImaginAb, Inc. forms European Subsidiary and Appoints General Manager-Europe

12 May 2021

news
news

ImaginAb and NEUVOGEN Announce Licensing Agreement for CD8 ImmunoPET Technology

28 Jan 2021

news
news

ImaginAb Announces License and Supply Agreement with Pfizer for CD8 ImmunoPET Technology

07 Jan 2021

news
news

Clarity Pharmaceuticals and ImaginAb to collaborate on new cancer targets

20 Jul 2020

news
news

ImaginAb and ARTMS Announce Strategic Partnership for Innovative Manufacture of 89Zr CD8 ImmunoPET Agent

07 Apr 2020

news
news

ImaginAb Announces Licensing Deal with AstraZeneca for CD8 ImmunoPET Technology

30 Mar 2020

news
news

ImaginAb Initiates Phase II Clinical Trial at Penn Medicine

09 Dec 2019

news
news

ImaginAb signs multi-party collaboration agreement with three global pharmaceutical companies to help further develop company’s CD8 ImmunoPET technology

13 Oct 2019

news
news

IMAGINAB TO PRESENT AT INNOVATION SHOWCASE 2019 HOSTED BY THE LUNDQUIST INSTITUTE

09 Oct 2019

news
news

ImaginAb Announces Publication of Data on First-In-Human Imaging in Patients with Solid Malignancies in The Journal of Nuclear Medicine

07 Oct 2019

news
news

ImaginAb Announces participation in Innovative Medicines Initiative ‘Immune cells in the spotlight’

01 Oct 2019

news
news

Dr. James Allison’s gripping documentary, Breakthrough

27 Sep 2019

news
news

ImaginAb Enrolls First Patient at the University of Alabama at Birmingham in On-going “Base Line/On Therapy” (BOT) Phase II Clinical Trial

25 Sep 2019

news
news

ImaginAb to Present at Upcoming Investor and Scientific Conferences in September & October 2019

04 Sep 2019

news
news

ImaginAb Initiates Phase II Clinical Trial at a World-Leading Cancer Center

24 Jul 2019

news
news

ImaginAb Announces Collaboration on CD8 Imaging Agent with Roche

09 Jul 2019

news
news

ImaginAb to Present at SNMMI 2019 Annual Meeting

20 Jun 2019

news
news

ImaginAb to Present at Upcoming Investor and Scientific Conferences in May and June 2019

30 May 2019

news
news

ImaginAb Enrolls First Patient in Phase II Clinical Trial at a World-Leading Cancer Center in Los Angeles County

16 May 2019

news
news

ImaginAb to Present at Upcoming Investor and Scientific Conferences in April and May 2019

17 Apr 2019

news
news

AACR Elects ImaginAb Science Advisory Board Member, Dr. Antoni Ribas, as President-Elect at 2019 Annual Meeting

04 Apr 2019

news
news

ImaginAb to Present at the American Association for Cancer Research Annual Meeting 2019

02 Apr 2019

news
news

ImaginAb Announces change in management and strengthening of the Board of Directors and the Scientific Advisory Board

27 Feb 2019

news
news

ImaginAb Enrolls First Patient in Phase II Clinical Trial

18 Jan 2019

news
news

ImaginAb Announces Immuno-Oncology License and Clinical Trial Collaboration with Nektar Therapeutics

03 Jan 2019

news
news

ImaginAb Strengthens Board and Executive Leadership Team

02 Jan 2019

news
news

Collaboration with Merck Imaging Agent

08 Oct 2018

news
news

ImaginAb and CPDC Announce Clinical Trial Supply Manufacture and Distribution Agreement for ImaginAb’s CD8 Immuno PET Tracer

29 Aug 2018

news
news

ImaginAb Appoints James Allison, Padmanee Sharma and Ramy Ibrahim to Scientific Advisory Board

09 Jul 2018

news
news

ImaginAb Reconstitutes Japanese Subsidiary

22 Jun 2018

news
news

ImaginAb Reconstitutes Scientific Advisory Board

17 May 2018

news
news

ImaginAb Appoints Ian Wilson as Chief Operating Officer

06 Feb 2018

news
news

ImaginAb Closes $8 million New Funding to Accelerate Clinical Development of CD8 ImmunoPET Agent

09 Oct 2017

news
news

ImaginAb Inc. Announces Strategic Collaboration with Boehringer Ingelheim to Develop New Technology for Monitoring Anti-tumor Activity of the Immune System

25 Sep 2017

news
news

ImaginAb Appoints Martyn Coombs as New Chief Executive Officer

22 Mar 2017

ImaginAb
  • Challenge
  • Create
  • Transform
info@imaginab.com
busdev@imaginab.com
US: +1.310.645.1211
EU: +44 (0) 1344 390 536
  • facebook
  • twitter
  • linkedin
ImaginAb, 423 Hindry Ave. Suite D, Inglewood, CA 90301
ImaginAb Europe, Lily Hill House, Room 11, Bracknell, Berks, RG12 2SJ, UK
© Copyright 2021 All rights reserved
  • Cookie Policy
  • Privacy Policy
  • Terms of Use

This website uses cookies

We use cookies to personalize content and ads, and to analyze our traffic and improve our service. Our website uses cookies to remember you and distinguish you from other users of our website. This helps us to provide you with a good experience when you browse our website and also allows us to improve our site.

Cookies that the site cannot function properly without. This includes cookies for access to secure areas and CSRF security. Please note that Craft’s default cookies do not collect any personal or sensitive information. Craft's default cookies do not collect IP addresses. The information they store is not sent to Pixel & Tonic or any 3rd parties.
Name: CraftSessionId
Description: Craft relies on PHP sessions to maintain sessions across web requests. That is done via the PHP session cookie. Craft names that cookie “CraftSessionId” by default, but it can be renamed via the phpSessionId config setting. This cookie will expire as soon as the session expires.
Provider: this site
Expiry: Session
Name: *_identity
Description: When you log into the Control Panel, you will get an authentication cookie used to maintain your authenticated state. The cookie name is prefixed with a long, randomly generated string, followed by _identity. The cookie only stores information necessary to maintain a secure, authenticated session and will only exist for as long as the user is authenticated in Craft.
Provider: this site
Expiry: Persistent
Name: *_username
Description: If you check the "Keep me logged in" option during login, this cookie is used to remember the username for your next authentication.
Provider: this site
Expiry: Persistent
Name: CRAFT_CSRF_TOKEN
Description: Protects us and you as a user against Cross-Site Request Forgery attacks.
Provider: this site
Expiry: Session
Statistic cookies help us understand how visitors interact with websites by collecting and reporting information anonymously.
Name: _ga
Description: Analytics
Provider: google.com
Expiry: 2 years
Details Hide Details
COOKIES